Herbal Supplement Interaction in a Diabetic Patient on Warfarin
Mr. Karim, a 66-year-old man with type 2 diabetes and atrial fibrillation, takes warfarin, metformin, and gliclazide. He visits a community pharmacy in Dhaka and asks about a "herbal diabetes cure" containing bitter gourd (Momordica charantia), fenugreek (Trigonella foenum-graecum), and ginkgo (Ginkgo biloba), sold as a powder with no listed quantities. His recent INR was 2.4 (target 2–3) and his fasting glucose is 7.8 mmol/L. He reports occasional dizziness and one episode of hypoglycemia-like sweating after taking the powder. He wants to know if he can stop metformin and use the herbal product instead.
1. Assess the risks of this herbal product in this patient and explain why it is not a substitute for metformin.
Read the worked answer
This product is a genuine safety concern. Bitter gourd and fenugreek both have glucose-lowering effects, and fenugreek seeds contain soluble fiber that can slow carbohydrate absorption; combined with gliclazide and metformin, they increase the risk of hypoglycemia, which may explain his sweating episode. The product's unquantified doses make the risk unpredictable, and adulteration of unregulated herbal powders with conventional drugs (including sulfonylureas) is a documented problem in many markets.
Ginkgo is the most worrying component for this patient. Ginkgo may inhibit platelet-activating factor and has been associated with bleeding, and case reports link it to increased INR and bleeding when combined with warfarin. His INR of 2.4 is therapeutic but could drift upward, especially with any change in diet or supplement use. Dizziness could reflect hypotension, hypoglycemia, or occult bleeding.
Metformin should not be stopped. It is a cornerstone therapy with proven cardiovascular benefit and a different mechanism from the herbals. Replacing it with an unstandardized product would leave his diabetes inadequately controlled and remove proven protection.
Advice: do not start the product until discussed with his physician; if he insists, monitor glucose and INR closely, and educate about hypoglycemia symptoms.
2. If the patient decides to use the product anyway, what monitoring plan and counseling would you provide?
Read the worked answer
Respect patient autonomy while minimizing harm. A structured plan:
- Inform the prescriber and document the supplement in the medication record so all clinicians know.
- Glucose monitoring: Check fasting and occasional postprandial glucose, and teach recognition and treatment of hypoglycemia (15 g fast-acting carbohydrate, recheck in 15 minutes). Consider reducing the gliclazide dose only in consultation with the physician, since the herbal glucose-lowering effect is additive.
- INR monitoring: Check INR within 1–2 weeks of starting, then more frequently, and whenever the product or its dose changes. Watch for bruising, gum bleeding, dark stools, or unusual headache.
- Symptom review: Investigate the dizziness; check blood pressure, glucose at the time of symptoms, and hemoglobin.
- Product quality: Advise buying from a reputable source with a labeled composition, and avoid products making disease-cure claims. Report suspected adverse reactions to the national pharmacovigilance authority.
- Counseling: Emphasize that the product is adjunctive at best, not a replacement, and that stopping metformin is not advised. Encourage consistency in diet and supplement intake so INR variability is minimized.